Members of the Philippine Food and Drug Administration (FDA) are slated to visit Gamaleya Institute’s manufacturing facility in Russia next week.
This comes in line with the FDA’s anticipated approval of emergency use authorization (EUA) of the Sputnik V vaccine in the country.
RELATED STORY: Galvez: Russia’s Sputnik V may receive emergency approval in 1-2 weeks
FDA Director-General Eric Domingo said: “Two weeks is the best-case scenario. Might extend if not all findings are compliant.”
As of this posting, Domingo said they are still waiting for “a few documents” from Gamaleya.
Earlier, Foreign Affairs Secretary Teodoro Locsin, Jr. shared that Manila may get up to 20 million doses of the Russian-made vaccine.
READ ON: JUST IN: Sputnik V vaccine 91.6% effective in late-stage trial, peer-review results say
“[I]n two weeks there’s the EUA for the Russian vaccine which could amount to another 20 million doses of the only Lancet peer-reviewed vaccine on the planet. Working on that,” he tweeted on Tuesday.
Sputnik V is the world’s first registered vaccine, with 91.6 percent efficacy against Covid-19 as validated by internationally peer-reviewed data published in the medical journal The Lancet.
The efficacy rate was based on the analysis of data on 19,866 volunteers on its human clinical trial.
